Sentences with phrase «change current programs»

After that they use the information to change current programs and design new ones to attract new students to the school.

If Ferguson's plan to change the current programs are passed, student loans should still be paid in full.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The Desk's current overnight Securities Lending operation will continue with no changes to program terms.

«Consistent with its pattern for the last two years, the company is on track to complete its regular review and thorough analysis and to announce any changes to the current program by March or April of 2014.

Our experience has been that such efficiency gains are not sustainable and that, without the elimination of programs and / or changes to the terms and conditions of current programs, incremental funding will be required.

The Rotman School has close ties to industry, and to stay current with the changing pace of business, the School invites local business leaders to participate in a vital executive - in - residence program.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry (R) World (TM); risks related to the collection, storage, transmission, use and disclosure of confidential and personal information;

Consistent with its pattern for the last two years, the Company is on track to complete its regular review and thorough analysis and to announce any changes to the current program by March or April of 2014.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

This program is designed for executive management teams seeking to change or improve their current business success.

Public Service Loan Forgiveness changes have been in the news a lot lately, from President Donald Trump's proposal to end the program for new borrowers to the mishandling of current loans by servicers.

The program was first launched in 2008 as the Seal of Excellence program and then changed to its current name in 2012.

Responding to a recent article in Nature on the psychology of climate change, The Guardian «s Andrew Brown argues that combatting global warming will require something beyond carbon taxes, recycling programs, and technological innovation: There may be ways of fixing [the current....

She concludes that «congregations that do not try new programs and new forms of outreach when they are faced with environmental change are not likely to survive past the life spans of their current members.»

The «Game of Change» was a seminal moment in sports, and the current Ramblers embrace their program's role in it.

As noted above, these awards can change over time, or even be discontinued, so make sure to contact the college or university regarding their current sibling discount program.

Attorneys representing all current and former NCAA student - athletes announced date changes made by the court, affecting the concussions settlement that will provide a 50 - year medical - monitoring program for student - athletes to screen for post-concussion syndrome and early - onset neurodegenerative disease that may have resulted from concussions or the accumulation of subconcussive hits while playing NCAA sports.

Evaluate your current foodservice program to establish a baseline of your operations and identify opportunities for change.

If one is to be successful, radical changes to the current programs are necessary.

The program offers state - of - the - art vending machines that don't «eat» the change and fail to dispense product (as the current ones have a habit of doing), uses far less energy, increases profits and is easy to use.»

They make sure our Healthy Schools Program is up to date with the most current best practices and provide the latest resources to support school leaders in their efforts to make sustainable change on their campuses.

By gaining extensive education in a variety of disciplines, program graduates will be poised to change the current standards of what it means to be a Doula in North America.

The Australian government has announced a major program of reform with the move to primary maternity care, a program of change that appears to be at odds with current general public perceptions regarding how maternity care is delivered.

The reform represents a program of change that appears to be at odds with current general public perceptions regarding how maternity care is delivered.

A decade later, nothing has changed; that's why it is disconcerting to see so much hype about the IDEO plan, which is still years away from implementation or affordability, but no talk about the current meal program.

While demographics in the Unites States have changed dramatically since Social Security's inception in 1935, Crowley said that there is no need to restructure the program, even with President Obama's own experts saying the fund is unsustainable at its current ratio of workers to benefit recipients.

The proposed NYS Executive Budget for Fiscal 2010 includes dramatic changes to the Empire Zone program that, if adopted, would significantly affect current program participants and limit new business certifications.

Under the change, some current convicts in prison would have the chance to appeal to have their prison sentences switched to treatment programs, which is great news for many serving now.

Recently, he announced approval of a comprehensive package of legislation that would help to preserve Mitchell - Lama housing by increasing protections for current tenants and changing eligibility requirements to allow more middle - class families to participate in the program.

But critics say these changes are a tacit acknowledgement by the governor that the program in its current form has been a failure.

It keeps the current system for those 55 and older, but for those 55 and younger, the structure of the Medicare program would significantly change.

If there is to be a change in policy, the new policy should be applied for next year's incoming kindergarten class, and all current students in the G&T program in P.S. 122Q should be allowed to continue so that the students can auto - articulate into their own middle school.

The Administration proposes to restructure the current Climate and Land Use Change program, eliminating $ 11.1 million in climate research and development activities and reducing Interior's Climate Science Centers (CSCs) by $ 8.5 million, halving the number of regional CSCs from eight to four.

A current project focuses on evaluating programs that aim to change behaviors that lead to teen pregnancy and sexually transmitted infections; the goal of the research is to see which programs work and assess their cost - effectiveness.

The commission says that the current rules under Horizon 2020, the European Union's science program, are «appropriate and will not change.»

China still draws 82 percent of energy from coal, but large dams are crucial to the country's climate change program, which aims to increase its proportion of electricity from renewable resources from the current 7.2 percent to 15 percent by 2020.

However, she said, if students are changing schools because of dissatisfaction with their current school, the program can have a significant impact on some groups.

But the decision, which has not yet been formally announced, is sure to spark opposition from Senator Richard Shelby (R - AL) and other members who fear that any change to the current Constellation rocket program will lead to mass layoffs in their states.

«Current federal policy that allows the mining industry to operate next to America's national icons and against the will of local communities must be changed,» said Jane Danowitz, Pew's U.S. public lands program director.

The current presidential administration in the US has proposed to almost completely eliminate funding for programs aimed at researching and reducing the effects of climate change.

(1) establish programs for assessing the current and future impacts of climate change and ocean acidification on natural resources within the department's or agency's, respectively, jurisdiction, including cumulative and synergistic effects, and for identifying and monitoring those natural resources that are likely to be adversely affected and that have need for conservation;

Three years ago, the agency's Game Changing Development program backed Kilopower, with the goal of building and testing a small fission reactor by Sept. 30, 2017, the end of the current fiscal year.

The authors found that this «health halo» encouraged overconsumption and underestimation of calories consumed, adding that the current study could lead to important changes in advertising regulations — for example, limiting how much information about its social programs a company may include on its food packaging.

g (acceleration due to gravity) G (gravitational constant) G star G1.9 +0.3 gabbro Gabor, Dennis (1900 — 1979) Gabriel's Horn Gacrux (Gamma Crucis) gadolinium Gagarin, Yuri Alexeyevich (1934 — 1968) Gagarin Cosmonaut Training Center GAIA Gaia Hypothesis galactic anticenter galactic bulge galactic center Galactic Club galactic coordinates galactic disk galactic empire galactic equator galactic habitable zone galactic halo galactic magnetic field galactic noise galactic plane galactic rotation galactose Galatea GALAXIES galaxy galaxy cannibalism galaxy classification galaxy formation galaxy interaction galaxy merger Galaxy, The Galaxy satellite series Gale Crater Galen (c. AD 129 — c. 216) galena GALEX (Galaxy Evolution Explorer) Galilean satellites Galilean telescope Galileo (Galilei, Galileo)(1564 — 1642) Galileo (spacecraft) Galileo Europa Mission (GEM) Galileo satellite navigation system gall gall bladder Galle, Johann Gottfried (1812 — 1910) gallic acid gallium gallon gallstone Galois, Évariste (1811 — 1832) Galois theory Galton, Francis (1822 — 1911) Galvani, Luigi (1737 — 1798) galvanizing galvanometer game game theory GAMES AND PUZZLES gamete gametophyte Gamma (Soviet orbiting telescope) Gamma Cassiopeiae Gamma Cassiopeiae star gamma function gamma globulin gamma rays Gamma Velorum gamma - ray burst gamma - ray satellites Gamow, George (1904 — 1968) ganglion gangrene Ganswindt, Hermann (1856 — 1934) Ganymede «garbage theory», of the origin of life Gardner, Martin (1914 — 2010) Garneau, Marc (1949 ---RRB- garnet Garnet Star (Mu Cephei) Garnet Star Nebula (IC 1396) garnierite Garriott, Owen K. (1930 ---RRB- Garuda gas gas chromatography gas constant gas giant gas laws gas - bounded nebula gaseous nebula gaseous propellant gaseous - propellant rocket engine gasoline Gaspra (minor planet 951) Gassendi, Pierre (1592 — 1655) gastric juice gastrin gastrocnemius gastroenteritis gastrointestinal tract gastropod gastrulation Gatewood, George D. (1940 ---RRB- Gauer - Henry reflex gauge boson gauge theory gauss (unit) Gauss, Carl Friedrich (1777 — 1855) Gaussian distribution Gay - Lussac, Joseph Louis (1778 — 1850) GCOM (Global Change Observing Mission) Geber (c. 720 — 815) gegenschein Geiger, Hans Wilhelm (1882 — 1945) Geiger - Müller counter Giessler tube gel gelatin Gelfond's theorem Gell - Mann, Murray (1929 ---RRB- GEM «gemination,» of martian canals Geminga Gemini (constellation) Gemini Observatory Gemini Project Gemini - Titan II gemstone gene gene expression gene mapping gene pool gene therapy gene transfer General Catalogue of Variable Stars (GCVS) general precession general theory of relativity generation ship generator Genesis (inflatable orbiting module) Genesis (sample return probe) genetic code genetic counseling genetic disorder genetic drift genetic engineering genetic marker genetic material genetic pool genetic recombination genetics GENETICS AND HEREDITY Geneva Extrasolar Planet Search Program genome genome, interstellar transmission of genotype gentian violet genus geoboard geode geodesic geodesy geodesy satellites geodetic precession Geographos (minor planet 1620) geography GEOGRAPHY Geo - IK geologic time geology GEOLOGY AND PLANETARY SCIENCE geomagnetic field geomagnetic storm geometric mean geometric sequence geometry GEOMETRY geometry puzzles geophysics GEOS (Geodetic Earth Orbiting Satellite) Geosat geostationary orbit geosynchronous orbit geosynchronous / geostationary transfer orbit (GTO) geosyncline Geotail (satellite) geotropism germ germ cells Germain, Sophie (1776 — 1831) German Rocket Society germanium germination Gesner, Konrad von (1516 — 1565) gestation Get Off the Earth puzzle Gettier problem geyser g - force GFO (Geosat Follow - On) GFZ - 1 (GeoForschungsZentrum) ghost crater Ghost Head Nebula (NGC 2080) ghost image Ghost of Jupiter (NGC 3242) Giacconi, Riccardo (1931 ---RRB- Giacobini - Zinner, Comet (Comet 21P /) Giaever, Ivar (1929 ---RRB- giant branch Giant Magellan Telescope giant molecular cloud giant planet giant star Giant's Causeway Giauque, William Francis (1895 — 1982) gibberellins Gibbs, Josiah Willard (1839 — 1903) Gibbs free energy Gibson, Edward G. (1936 ---RRB- Gilbert, William (1544 — 1603) gilbert (unit) Gilbreath's conjecture gilding gill gill (unit) Gilruth, Robert R. (1913 — 2000) gilsonite gimbal Ginga ginkgo Giotto (ESA Halley probe) GIRD (Gruppa Isutcheniya Reaktivnovo Dvisheniya) girder glacial drift glacial groove glacier gland Glaser, Donald Arthur (1926 — 2013) Glashow, Sheldon (1932 ---RRB- glass GLAST (Gamma - ray Large Area Space Telescope) Glauber, Johann Rudolf (1607 — 1670) glaucoma glauconite Glenn, John Herschel, Jr. (1921 ---RRB- Glenn Research Center Glennan, T (homas) Keith (1905 — 1995) glenoid cavity glia glial cell glider Gliese 229B Gliese 581 Gliese 67 (HD 10307, HIP 7918) Gliese 710 (HD 168442, HIP 89825) Gliese 86 Gliese 876 Gliese Catalogue glioma glissette glitch Global Astrometric Interferometer for Astrophysics (GAIA) Global Oscillation Network Group (GONG) Globalstar globe Globigerina globular cluster globular proteins globule globulin globus pallidus GLOMR (Global Low Orbiting Message Relay) GLONASS (Global Navigation Satellite System) glossopharyngeal nerve Gloster E. 28/39 glottis glow - worm glucagon glucocorticoid glucose glucoside gluon Glushko, Valentin Petrovitch (1908 — 1989) glutamic acid glutamine gluten gluteus maximus glycerol glycine glycogen glycol glycolysis glycoprotein glycosidic bond glycosuria glyoxysome GMS (Geosynchronous Meteorological Satellite) GMT (Greenwich Mean Time) Gnathostomata gneiss Go Go, No - go goblet cell GOCE (Gravity field and steady - state Ocean Circulation Explorer) God Goddard, Robert Hutchings (1882 — 1945) Goddard Institute for Space Studies Goddard Space Flight Center Gödel, Kurt (1906 — 1978) Gödel universe Godwin, Francis (1562 — 1633) GOES (Geostationary Operational Environmental Satellite) goethite goiter gold Gold, Thomas (1920 — 2004) Goldbach conjecture golden ratio (phi) Goldin, Daniel Saul (1940 ---RRB- gold - leaf electroscope Goldstone Tracking Facility Golgi, Camillo (1844 — 1926) Golgi apparatus Golomb, Solomon W. (1932 — 2016) golygon GOMS (Geostationary Operational Meteorological Satellite) gonad gonadotrophin - releasing hormone gonadotrophins Gondwanaland Gonets goniatite goniometer gonorrhea Goodricke, John (1764 — 1786) googol Gordian Knot Gordon, Richard Francis, Jr. (1929 — 2017) Gore, John Ellard (1845 — 1910) gorge gorilla Gorizont Gott loop Goudsmit, Samuel Abraham (1902 — 1978) Gould, Benjamin Apthorp (1824 — 1896) Gould, Stephen Jay (1941 — 2002) Gould Belt gout governor GPS (Global Positioning System) Graaf, Regnier de (1641 — 1673) Graafian follicle GRAB graben GRACE (Gravity Recovery and Climate Experiment) graceful graph gradient Graham, Ronald (1935 ---RRB- Graham, Thomas (1805 — 1869) Graham's law of diffusion Graham's number GRAIL (Gravity Recovery and Interior Laboratory) grain (cereal) grain (unit) gram gram - atom Gramme, Zénobe Théophile (1826 — 1901) gramophone Gram's stain Gran Telescopio Canarias (GTC) Granat Grand Tour grand unified theory (GUT) Grandfather Paradox Granit, Ragnar Arthur (1900 — 1991) granite granulation granule granulocyte graph graph theory graphene graphite GRAPHS AND GRAPH THEORY graptolite grass grassland gravel graveyard orbit gravimeter gravimetric analysis Gravitational Biology Facility gravitational collapse gravitational constant (G) gravitational instability gravitational lens gravitational life gravitational lock gravitational microlensing GRAVITATIONAL PHYSICS gravitational slingshot effect gravitational waves graviton gravity gravity gradient gravity gradient stabilization Gravity Probe A Gravity Probe B gravity - assist gray (Gy) gray goo gray matter grazing - incidence telescope Great Annihilator Great Attractor great circle Great Comets Great Hercules Cluster (M13, NGC 6205) Great Monad Great Observatories Great Red Spot Great Rift (in Milky Way) Great Rift Valley Great Square of Pegasus Great Wall greater omentum greatest elongation Green, George (1793 — 1841) Green, Nathaniel E. Green, Thomas Hill (1836 — 1882) green algae Green Bank Green Bank conference (1961) Green Bank Telescope green flash greenhouse effect greenhouse gases Green's theorem Greg, Percy (1836 — 1889) Gregorian calendar Grelling's paradox Griffith, George (1857 — 1906) Griffith Observatory Grignard, François Auguste Victor (1871 — 1935) Grignard reagent grike Grimaldi, Francesco Maria (1618 — 1663) Grissom, Virgil (1926 — 1967) grit gritstone Groom Lake Groombridge 34 Groombridge Catalogue gross ground, electrical ground state ground - track group group theory GROUPS AND GROUP THEORY growing season growth growth hormone growth hormone - releasing hormone growth plate Grudge, Project Gruithuisen, Franz von Paula (1774 — 1852) Grus (constellation) Grus Quartet (NGC 7552, NGC 7582, NGC 7590, and NGC 7599) GSLV (Geosynchronous Satellite Launch Vehicle) g - suit G - type asteroid Guericke, Otto von (1602 — 1686) guanine Guiana Space Centre guidance, inertial Guide Star Catalog (GSC) guided missile guided missiles, postwar development Guillaume, Charles Édouard (1861 — 1938) Gulf Stream (ocean current) Gulfstream (jet plane) Gullstrand, Allvar (1862 — 1930) gum Gum Nebula gun metal gunpowder Gurwin Gusev Crater gut Gutenberg, Johann (c. 1400 — 1468) Guy, Richard Kenneth (1916 ---RRB- guyot Guzman Prize gymnosperm gynecology gynoecium gypsum gyrocompass gyrofrequency gyropilot gyroscope gyrostabilizer Gyulbudagian's Nebula (HH215)

This fitness program (or regimen) ignites a change in perspective of current...

This fitness program (or regimen) ignites a change in perspective of current fitness trends.

Utilizing Skinny Fit detox tea reducing program without make changes to the lifestyle which has caused the current states of being heavy or otherwise unhealthy, may provide some short term favorable effects.

If you're still making good gains with your current program, then you shouldn't change a thing.